Meropenem and Failure to thrive - a phase IV clinical study of FDA data

Summary:

Failure to thrive is reported as a side effect among people who take Meropenem (meropenem), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lasix, and have Hypothyroidism.

The phase IV clinical study analyzes which people have Failure to thrive when taking Meropenem. It is created by eHealthMe based on reports of 33,250 people who have side effects when taking Meropenem from the FDA, and is updated regularly.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

What is Failure to thrive?

Failure to thrive (inadequate weight gain and physical growth in children) is found to be associated with 772 drugs and 1,168 conditions by eHealthMe. Check the latest studies of Failure to thrive.

On Jul, 11, 2026

33,250 people reported to have side effects when taking Meropenem.
Among them, 24 people (0.07%) have Failure to thrive.

Could Meropenem cause Failure to thrive?

Among these 24 people:

How long have people been on Meropenem when they have Failure to thrive? *

What is the gender of people who have Failure to thrive when taking Meropenem? *

female: 30.43 %
male: 69.57 %

What is the age of people who have Failure to thrive when taking Meropenem? *

What are other drugs people take besides Meropenem? *

Lasix: 14 people, 58.33%
Benzonatate: 12 people, 50.00%
Potassium Chloride: 11 people, 45.83%
Zetia: 11 people, 45.83%
Levofloxacin: 11 people, 45.83%
Aspirin: 11 people, 45.83%
Zocor: 11 people, 45.83%
Coreg: 11 people, 45.83%
Levothyroxine Sodium: 10 people, 41.67%
Vancomycin Hydrochloride: 5 people, 20.83%

What are other side effects people have besides Failure to thrive? *

Orthostatic Hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up): 14 people, 58.33%
Intestinal Obstruction: 13 people, 54.17%
Lung Cancer - Non-Small Cell (lung cancer): 12 people, 50.00%
Constipation: 12 people, 50.00%
Disease Progression: 8 people, 33.33%
Loss Of Consciousness: 3 people, 12.50%
Fatigue (feeling of tiredness): 3 people, 12.50%
Fall: 3 people, 12.50%
Oedema Peripheral (superficial swelling): 3 people, 12.50%
Dyspnea (difficult or laboured breathing): 2 people, 8.33%

What are the existing conditions these people have? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 13 people, 54.17%
Lung Cancer - Non-Small Cell (lung cancer): 12 people, 50.00%
Cough: 12 people, 50.00%
High Blood Pressure: 12 people, 50.00%
Hyperlipidaemia (presence of excess lipids in the blood): 12 people, 50.00%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 5 people, 20.83%
Sepsis (a severe blood infection that can lead to organ failure and death): 3 people, 12.50%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 8.33%
Multiple Myeloma (cancer of the plasma cells): 2 people, 8.33%
Mucosal Inflammation (infection of mucous membrane): 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Meropenem and have Failure to thrive?

- Check whether Failure to thrive is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Meropenem:

Meropenem (33,295 reports)

Browse all side effects of Meropenem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Failure to thrive:

Failure to thrive (772 drugs)

Browse all the conditions that are associated with Failure to thrive:

Failure to thrive (1,168 conditions)

Related publications that referenced our studies

Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on meropenem (the active ingredients of Meropenem) and Meropenem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.